[Oncogene expression in adriamycin and platinum resistant cell lines].
Using dot hybridization and southern blot technique, we studied the oncogene expression in P388/ADR and L1210/cis-platinum resistant cell lines. The amplification of three oncogene probes (C-myc, v-erb-B, N-ras) controlled with beta-actin in P388/ADR resistant cells was decreased by 1.335, 1.695, 1.35-fold (P < 0.05) (drug-resistant 44.5-fold), and 2.195, 2.02, 1.854-fold (P < 0.05) (drug-resistant 23.6-fold) respectively compared with P388/0 sensitive cell lines, and 1.950-, 2.075-, 2.285-fold (P < 0.05) (drug-resistant 3.5-fold) in L1210/cis-platinum compared with L1210/0 sensitive cell lines. The three oncogene amplification in resistant cell lines was not changed when southern blot hybridage was used. These results show that the more resistant the multidrug resistant cell lines is the worse the potential multiplication and prognosis of the tumor with be.
Liu
Y B
YB
Department of Clinical Pharmacology, North Taiping Road Hospital, Beijing.
D000818:Animals; D002945:Cisplatin / Q000494:pharmacology*; D004317:Doxorubicin / Q000494:pharmacology*; D004351:Drug Resistance / Q000235:genetics*; D005260:Female; D015870:Gene Expression; D016259:Genes, myc; D011905:Genes, ras; D007939:Leukemia L1210 / Q000235:genetics* / Q000473:pathology; D007941:Leukemia P388 / Q000235:genetics* / Q000473:pathology; D008297:Male; D051379:Mice; D008811:Mice, Inbred DBA; D018739:Oncogene Proteins v-erbB; D015682:Retroviridae Proteins, Oncogenic / Q000235:genetics; D014407:Tumor Cells, Cultured / Q000187:drug effects
D018739:Oncogene Proteins v-erbB; D015682:Retroviridae Proteins, Oncogenic; D004317:Doxorubicin; D002945:Cisplatin